Polmacoxib, a nonsteroidal anti-inflammatory drug (NSAID) with unique dual mechanisms, was developed primarily for managing osteoarthritis. It functions as a selective COX-2 inhibitor and also modulates calcium channel activity. Clinical trials began in the early 2000s, focusing on its efficacy in pain relief while reducing gastrointestinal and cardiovascular risks typically associated with NSAIDs. Polmacoxib received its first regulatory approval in South Korea in 2015 under the trade name Acelex, following promising Phase III trials that demonstrated significant improvements in pain management with a favourable safety profile.

Polmacoxib is primarily indicated for:

• Osteoarthritis: To alleviate pain, improve joint function, and reduce inflammation.
• Rheumatoid arthritis (off-label): Though not officially approved for this use, research suggests potential benefits for inflammatory arthritis.

Polmacoxib is available in oral tablet form, typically at a dose of 2 mg once daily. The dosage of polmacoxib may vary based on the severity of the condition, the patient's age, and overall health status. Always follow your healthcare provider’s recommendations for safe and effective use.

Common side effects of Polmacoxib include:

• Headache
• Dizziness
• Gastrointestinal discomfort (nausea, diarrhoea, or bloating)
• Fatigue
• Increased blood pressure

Seek prompt medical attention if you experience symptoms of an allergic reaction, severe chest pain, or signs of gastrointestinal bleeding.

• Cardiovascular Risk: Prolonged use may increase the risk of cardiovascular events such as heart attack or stroke, especially in patients with pre-existing conditions.
• Gastrointestinal Risk: Although Polmacoxib has reduced GI side effects compared to non-selective NSAIDs, it may still cause ulcers or bleeding in susceptible individuals.
• Kidney Function: Monitor renal function in patients with impaired kidney health, as Polmacoxib may cause fluid retention or renal toxicity.

• Pregnancy and Lactation: Polmacoxib is contraindicated in the third trimester due to the risk of fetal harm. Consult a healthcare provider before use during pregnancy or breastfeeding.
• Allergies: Avoid in patients with hypersensitivity to COX-2 inhibitors or sulfonamide-based drugs.
• Drug Interactions: Exercise caution when using Polmacoxib with anticoagulants, diuretics, or ACE inhibitors, as interactions may lead to increased toxicity or reduced efficacy.

Polmacoxib offers an effective alternative for managing osteoarthritis-related pain and inflammation. However, like all medications, it carries risks that require careful consideration. Always consult a doctor to determine if this medication aligns with your medical history and treatment goals. Avoid self-medicating and adhere to prescribed dosages.

1. Easwaran R, Mistry UK, Bhole M, Peethambaran K. Polmacoxib: A Review of the Newer Non-steroidal Anti-inflammatory Drug in Osteoarthritis. Cureus. 2024 Apr 17;16(4)https://pmc.ncbi.nlm.nih.gov/articles/PMC11099947/
2. https://go.drugbank.com/drugs/DB12399
3. https://www.sciencedirect.com/science/article/abs/pii/S0006291X16312360

This content is intended for informational purposes only and should not replace professional medical advice. Consult a licensed healthcare provider for diagnosis and treatment tailored to your specific health needs.